Archived: ranolazine (Ranexa)

Advice

following a resubmission:

ranolazine (Ranexa®) is not recommended for use within NHS Scotland.

Indication under review: as add-on therapy for the symptomatic treatment of patients with
stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal
therapies (such as beta blockers and/or calcium antagonists).

When added to standard doses of antianginal drugs, ranolazine increased exercise duration at
trough drug levels compared with placebo after 12 weeks treatment. Although significant the
effect size was modest.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance
by SMC.

The licence holder has indicated their intention to resubmit.